国产精品久久久久久永久牛牛,55国产福利在线视频,成人午夜精品视频在线观看

目錄產(chǎn)品 » 穩(wěn)定細(xì)胞系 » Human Recombinant κ-Opioid Receptor OPRK1 Stable Cell Line
CHO-K1/OPRK1/Gα15 Stable Cell Line

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with U-50488 in CHO-K1/OPRK1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/OPRK1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 42.36 nM.

CHO-K1/OPRK1/Gα15 Stable Cell Line

Figure 1. U-50488-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/OPRK1/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142; Molecular Devices) prior to stimulation with OPRK1 agonist, U-50488. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were recorded and normalized to plot against the log of the cumulative doses of U-50488 (mean ± SEM, n = 3). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 11.07 nM.

Notes:
EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^ ((LogEC50-X)*Hill Slope))
X is the logarithm of concentration. Y is the response.
Y is RFU and starts at Bottom and goes to Top along a sigmoid curve.

CHO-K1/OPRK1/Gα15 Stable Cell Line

Recombinant CHO-K1 cells stably overexpress human opioid receptor kappa 1 (OPRK1) on the surface and contain high levels of G protein Gαi to couple with the receptor in downstream signaling pathways.
M00290
詢價(jià)

聯(lián)系我們
Product Description Recombinant CHO-K1 cells stably overexpress human opioid receptor kappa 1 (OPRK1) on the surface and contain high levels of G protein Gαi to couple with the receptor in downstream signaling pathways.
Culture Properties Adherent
Stability Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size Two vials of frozen cells (>1×106 per vial in 1 mL)
Storage Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

Culture Medium Ham’s F-12K (Kaighn’s), 10% FBS, 200 μg/ml Zeocin (Cat. No. R250-01, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Life Technologies)
Complete Growth Medium Ham’s F-12K (Kaighn’s), 10% FBS
Freeze Medium-DATA 45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Life Technologies), 10% DMSO (Cat. No. D2650, Sigma)

  • CHO-K1/OPRK1/Gα15 Stable Cell Line
  • CHO-K1/OPRK1/Gα15 Stable Cell Line

    Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with U-50488 in CHO-K1/OPRK1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/OPRK1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 42.36 nM.

  • CHO-K1/OPRK1/Gα15 Stable Cell Line
  • CHO-K1/OPRK1/Gα15 Stable Cell Line

    Figure 1. U-50488-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/OPRK1/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142; Molecular Devices) prior to stimulation with OPRK1 agonist, U-50488. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were recorded and normalized to plot against the log of the cumulative doses of U-50488 (mean ± SEM, n = 3). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 11.07 nM.

    Notes:
    EC50 value is calculated with four parameter logistic equation:
    Y=Bottom + (Top-Bottom) / (1+10^ ((LogEC50-X)*Hill Slope))
    X is the logarithm of concentration. Y is the response.
    Y is RFU and starts at Bottom and goes to Top along a sigmoid curve.


For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.


喜歡新升級(jí)的網(wǎng)站嗎?

討厭

不喜歡

一般

喜歡

非常喜歡

*
    主站蜘蛛池模板: 九寨沟县| 华坪县| 娄底市| 阿城市| 原阳县| 兴海县| 汶上县| 大竹县| 广德县| 浠水县| 柞水县| 洛宁县| 莒南县| 弥勒县| 阿拉善左旗| 江陵县| 什邡市| 汤原县| 泽普县| 郎溪县| 安达市| 和静县| 长海县| 曲阜市| 大同市| 彰化县| 高州市| 诏安县| 始兴县| 许昌市| 桦甸市| 宣城市| 龙江县| 灵山县| 黔西县| 虞城县| 朝阳县| 永安市| 河北区| 巨野县| 湟中县|